Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of (177)Lu-DOTA-EB-TATE

This study aimed to evaluate the safety and efficacy of multiple cycles of (177)Lu-DOTA-Evans blue (EB)-TATE peptide receptor radionuclide therapy (PRRT) at escalating doses in neuroendocrine tumors (NETs). Methods: Thirty-two NET patients were randomly divided into 3 groups and treated with escalat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Nucl Med
Main Authors: Liu, Qingxing, Zang, Jie, Sui, Huimin, Ren, Jiakun, Guo, Hua, Wang, Hao, Wang, Rongxi, Jacobson, Orit, Zhang, Jingjing, Cheng, Yuejuan, Zhu, Zhaohui, Chen, Xiaoyuan
Formato: Artigo
Idioma:Inglês
Publicado em: Society of Nuclear Medicine 2021
Assuntos:
Theranostics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8049339/
https://ncbi.nlm.nih.gov/pubmed/32826319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.120.248658
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados